MarketScreener

Celcuity Q3 Adjusted Loss Widens

Celcuity reported a Q3 adjusted loss late Thursday of $1.21 per diluted share, widening from a loss of $0.78 a year earlier. Three analysts polled by FactSet expected a loss of $1.46. .
BIOENGINEER

Traditional Chinese Formula Shows Antifibrotic Effects Through PI3K/AKT Pathway

A traditional Chinese medicine formula reduced liver fibrosis in rat and cell models by down-regulating the PI3K/AKT ...
MarketScreener

Earnings Flash (CELC) Celcuity Inc. Posts Q3 Adjusted Loss $1.21 per Share, vs. FactSet Est of $-1.51

Oct. 24 Celcuity Inc. Presents Updated Results from the Pik3ca Mt Cohort of the Phase 3 Viktoria-1 Study in Patients with Hr+/Her2- Advanced Breast Cancer At the Esmo Congress 2026 CI Oct. 23 Celcuity ...

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase ...
BIOENGINEER

PIK3CA mutation rewires immune and metabolic networks in cervical cancer cells

CRISPR-engineered cervical cancer cells carrying the PIK3CA-E545K mutation show coordinated immune signaling and metabolic ...

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and ...

The colorectal cancer market is expected to grow steadily, driven by the rising incidence of colorectal cancer worldwide and increasing disease awareness. The adoption of targeted therapies, ...
Targeted Oncology

Defining Endocrine Resistance in PIK3CA-Mutated HR+/HER2-Negative Advanced Breast Cancer

Opinion|Videos|September 30, 2026 Defining Endocrine Resistance in PIK3CA-Mutated HR+/HER2-Negative Advanced Breast Cancer Author (s) Jason Mouabbi, MD Interact with this article Ask Scout! Ask ...
The American Journal of Managed Care

Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations

ASCOLT's translational study found no survival benefit from aspirin in either prespecified subgroup: PIK3CA mutations or COX-2 overexpression. Pooling it with SAKK 41/13 and ALASCCA gave a 39% ...
eLife

PIK3CA-related overgrowth spectrum (PROS) zebrafish models reveal pan-lineage developmental dysregulation

MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom Edinburgh Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, The ...
News Medical

Multimodal AI improves prediction of PIK3CA mutations in breast cancer

Breast cancer is one of the most common malignancies worldwide, and mutations in the PI3K/AKT/mTOR (PAM) signaling pathway are prevalent in its development. Among these, PIK3CA mutations play a ...
Scientific Research Publishing

Yamamoto, S., Tsuda, H., Takano, M., Tamai, S. and Matsubara, O. (2012) PIK3CA Mutations and Loss of ARID1A Protein Expression Are Early Events in the Development of Cystic ...

ABSTRACT: Background: Gynecologic clear cell carcinoma (CCC) represents a rare and biologically distinct subgroup of gynecologic malignancies arising predominantly from the ovary and endometrium, and ...
EurekAlert!

New AI framework offers reliable, cost-effective prediction of PIK3CA mutations in breast cancer

Accurate detection of PIK3CA mutations is essential for personalizing breast cancer treatment, particularly with PI3K-targeted therapies. However, conventional molecular testing is not always ...